Free Newsletter
New therapy found for schizophrenia
There are a wide range of cognitive disorders associated with schizophrenia: poor memory, impaired attention, difficulty with problem-solving. And the current class of drugs used to treat the hallucinations and delusions associated with schizophrenia have only a limited success with these cognitive disorders. But scientists at the Institute for Neurodegenerative Disorders report that they have identified a drug that has "a normalizing effect on the spontaneous activity of prefrontal cortex neurons." The therapy reverses chemically induced abnormalities in prefrontal cortical functioning. Researcher Bita Moghaddam says that their work can lead the way to the development of new therapies that are specifically targeted at these cognitive disorders.
- see this release
Related Articles:
Lilly's schizophrenia drug may offer breakthrough. Report
New schizophrenia drugs little better than the old. Report
Mice engineer to be schizophrenic. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Be the first to comment